Generate a tailored SOP for Dr. Michelle Hastings. Improve your application with a focused, well-structured draft.
Michelle L. Hastings is a Pfizer Upjohn Research Professor of Pharmacology at the University of Michigan Medical School and the Director of the M-RNA Therapeutics program. With a PhD from Marquette University, Dr. Hastings has developed a robust research portfolio focusing on genetic diseases and novel therapeutics to modulate RNA processing and alter gene expression. Her pioneering work has resulted in significant advancements, including the demonstration of recovery in hearing and balance in a genetic mouse model for human deafness, paving the way for potential treatments in humans. Her recent investigations have also shown that antisense technology can partially correct gene expression in forms of CLN3 Batten disease and cystic fibrosis. A recognized leader in her field, Dr. Hastings has numerous patents and has contributed to many high-impact publications. She has been featured in major media outlets, including BBC and NPR, highlighting her innovative research in RNA therapeutics. Dr. Hastings is a 2022 National Academy of Sciences Kavli Fellow and serves on several editorial and advisory boards, contributing to advancements in RNA science and its application in medicine.
University of Michigan Medical School • Ann Arbor, MI
Leading research in pharmacology and RNA therapeutics.
Admission for Biological Chemistry, Cellular and Molecular Biology, Human Genetics, Microbiology and Immunology, Pharmacology, Molecular and Integrative Physiology, Cancer Biology, and Neuroscience is primary handled through the PIBS (Program in Biomedical Sciences) gateway.